Drug intelligence / Profile preview

eliglustat + immune checkpoint inhibitor + regorafenib

Development stage: Unknown
Lead developer: Chinese PLA General Hospital
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This appears to be a combination of three different therapeutic agents: eliglustat (a glucosylceramide synthase inhibitor), an unspecified immune checkpoint inhibitor, and regorafenib (a multi-kinase inhibitor). Regorafenib is an oral multi-kinase inhibitor that blocks proteins involved in tumor growth and angiogenesis, approved for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. There is no established clinical use of this specific three-drug combination in current medical practice.

Targets

RAF1 (c-Raf-1 (Y340D/Y341D))PDCD1 (Programmed cell death protein 1 receptor)BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)UGCG (UDP-glucose ceramide glucosyltransferase)

Beyond the preview

Go deeper on eliglustat + immune checkpoint inhibitor + regorafenib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eliglustat + immune checkpoint inhibitor + regorafenib.

Explore the full profile